Plozasiran Cuts Pancreatitis Across Two Phase 3 Trials
Arrowhead’s plozasiran met the primary endpoint and every prespecified secondary endpoint in the Phase 3 SHASTA-3 and SHASTA-4 trials. Quarterly 25 mg dosing reduced median triglycerides by 79% and 81% at Month 12 and…
